Expression and Proliferation-Promoting Role of Lymphoid Enhancer-Binding Factor 1 in Human Clear Cell Renal Carcinoma

REFERENCES

• Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am 2012;39:119–132.
   PubMed Web of Science ®Google Scholar
• Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843–852.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.
   PubMed Web of Science ®Google Scholar
• Yu DS, Chang SY, Ma CP. The expression of MDR-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 1998;82:544–547.
   PubMedGoogle Scholar
• Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999;19:1541–1543.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S. Subcutaneous interleukin-2, interferon-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. J Clin Oncol 1998;16:2728–2732.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 1993;29:56–58.
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–3590.
   PubMed Web of Science ®Google Scholar
• Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract 2007;13:5–15.
   PubMedGoogle Scholar
• Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer 2013;11:283–289.
   PubMed Web of Science ®Google Scholar
• Mansueto G, Longo F. ASCO 2008. Bevacizumab in advanced renal carcinoma. Tumori 2008;94:15–23.
   Google Scholar
• Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997;11:24–27.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 2004;28:1267–1271.
   PubMed Web of Science ®Google Scholar
• Shang D, Liu Y, Matsui Y, Ito N, Kamoto T, Ogawa O. Demethylaing agent 5-Aza-2′-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology 2008;71:1220–1225.
   PubMed Web of Science ®Google Scholar
• Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W, Tian Y. Synergy of 5-aza-2’-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Letter 2009;278:82–87.
   PubMed Web of Science ®Google Scholar
• Shang D, Ito N, Kamoto T, Ogawa O. Demethylating agent 5-Aza-2-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology 2007;69:1007–1012.
   PubMed Web of Science ®Google Scholar
• Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286–3305.
   PubMed Web of Science ®Google Scholar
• Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311–320.
   PubMed Web of Science ®Google Scholar
• Nusse R. WNT targets: repression and activation. Trends in Genetics 1999;15:1–3.
   PubMed Web of Science ®Google Scholar
• Travis A, Amsterdam A, Belanger C, Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function. Genes Dev 1991;5:880–894.
   PubMed Web of Science ®Google Scholar
• Waterman ML, Fischer WH, Jones KA. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev 1991;5:656–669.
   PubMed Web of Science ®Google Scholar
• Li TW, Ting JT, Yokoyama N, Bernstein A, van de Wetering M, Waterman M. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Molecular and Cellular Biology 2006;26:5284–5299.
   PubMed Web of Science ®Google Scholar
• Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, Kriegl L, Kirchner T, Larue L, Dummer R, Hoek KS. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 2011; 24:631–642.
   PubMedGoogle Scholar
• Lin AY, Chua MS, Choi YL, Yeh W, Kim YH, Azzi R, Adams GA, Sainani K, van de Rijn M, So SK, Pollack JR. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 2011;6:e16636.
   PubMedGoogle Scholar
• Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010;115:2845–2851.
   PubMed Web of Science ®Google Scholar
• Gehrke I, Gandhirajan RK, Kreuzer KA. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur J Cancer 2009;45:2759–2767.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 2009;69:3332–3338.
   PubMed Web of Science ®Google Scholar
• Yun K, Im SH. Lef1 regulates COX-2 transcription in chondrocytes. Biochem Biophys Res Commun 2007;364:270–275.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Marafioti T, Paterson JC, Malcovati L, Della Porta MG, Jädersten M, Pushkaran B, George TI, Arber DA, Killick S, Giagounidis A, Hellström-Lindberg E, Cazzola M, Wainscoat JS, Boultwood J. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009;146:86–90.
   PubMed Web of Science ®Google Scholar
• Feigin ME, Malbon CC. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 2008;20:949–957.
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;1381;51–62.
   Google Scholar
• Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME. Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002;277:20702–20710.
   PubMed Web of Science ®Google Scholar
• Watermann ML. Lymphoid enhance factor/T cell factor expression in cplorectal cancer. Cancer Metastasis Rev 2004;23: 41–52.
   PubMedGoogle Scholar
• Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709–4713.
   PubMed Web of Science ®Google Scholar
• Brantjes H, Barker N, van Es J, Clevers H. TCF: lady justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 2002;383:255–261.
   PubMed Web of Science ®Google Scholar
• Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638–642.
   PubMed Web of Science ®Google Scholar
• Hovanes K1, Li TW, Waterman ML. The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res 2000;28:1994–2003.
   PubMed Web of Science ®Google Scholar
• Han T, Shang D, Xu X, Tian Y. Gene expression profiling of the synergy of 5-aza-2′-deoxycytidine and paclitaxel against renal cell carcinoma. World J Surg Oncol 2012;10:183.
   PubMedGoogle Scholar
• Shang D, Liu Y, Xu X, Han T, Tian Y. 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression. Cancer Lett 2011;311:230–236.
   PubMed Web of Science ®Google Scholar
• Nikuševa-Martić T1, Serman L, Zeljko M, Expression of secreted frizzled-related protein 1 and 3, T-cell factor 1 and lymphoid enhancer factor 1 in clear cell renal cell carcinoma. Pathol Oncol Res 2013;19:545–551.
   PubMed Web of Science ®Google Scholar